Nothing said here yet.
to join the conversation.
| Mancini AnthonySee Remarks | Sell | 2,310 | $431.9K | Mon, Oct 26 |
| Sandler Alan B.Chief Development Officer | Sell | 2,200 | $441.8K | Tue, Sep 29 |
| Sandler Alan B.Chief Development Officer | Sell | 1,609 | $324.6K | Tue, Sep 29 |
| Sandler Alan B.Chief Development Officer | Sell | 1,199 | $244.5K | Tue, Sep 29 |
| Sandler Alan B.Chief Development Officer | Sell | 1,000 | $202.8K | Tue, Sep 29 |
| Sandler Alan B.Chief Development Officer | Sell | 301 | $61.6K | Tue, Sep 29 |
| Mancini AnthonySee Remarks | Sell | 3,121 | $625.9K | Fri, Sep 25 |
| Cislini JeffSVP & General Counsel | Sell | 765 | $158.6K | Fri, Sep 25 |
| Mancini AnthonySee Remarks | Sell | 587 | $117.4K | Thu, Sep 24 |
| ANDERSON ELIZABETH MDirector | Sell | 4,985 | $959.8K | Tue, Sep 22 |
| ANDERSON ELIZABETH MDirector | Sell | 2,648 | $512.2K | Tue, Sep 22 |
| ANDERSON ELIZABETH MDirector | Sell | 1,500 | $291.9K | Tue, Sep 22 |
BOSTON, 30. októbra 2026 /PRNewswire/ – Dr. Yang Liu, riaditeľ oddelenia medicínskej chémie v spoločnosti Revolution Medicines, Inc., a Dr. Kristof Pota, vedúci vedecký pracovník, navštívili výskumné a vývojové centrum Nanhui spoločnosti Medicilon.
BOSTON, 30 octobre 2026 /PRNewswire/ -- Le Dr Yang Liu, directeur de la chimie médicinale chez Revolution Medicines, Inc., et le Dr Kristof Pota, scientifique principal, ont visité le centre de R&D de Medicilon à Nanhui.
BOSTON, 30 października 2026 r. /PRNewswire/ -- Dr Yang Liu, dyrektor ds. chemii medycznej w Revolution Medicines, Inc., oraz dr Kristof Pota, starszy naukowiec, odwiedzili Centrum Badawczo-Rozwojowe Medicilon w Nanhui.
BOSTON, 30 de octubre de 2026 /PRNewswire/ -- El doctor Yang Liu, director de Química Médica de Revolution Medicines, Inc., y el doctor Kristof Pota, científico sénior, visitaron el Centro de I+D de Medicilon en Nanhui.
BOSTON, 30. října 2026 /PRNewswire/ -- Dr. Yang Liu, ředitel oddělení medicínské chemie ve společnosti Revolution Medicines, Inc., a Dr. Kristof Pota, vedoucí vědecký pracovník, navštívili výzkumné a vývojové centrum společnosti Medicilon v Nan-chuej.
BOSTON, 30. Oktober 2026 /PRNewswire/ -- Dr. YangLiu, Leiter der Abteilung für medizinische Chemie bei Revolution Medicines, Inc., und Dr. Kristof Pota, leitender Wissenschaftler, besuchten das Forschungs- und Entwicklungszentrum von Medicilon in Nanhui.
The number of patients actively using Optune Pax in the U.S. declined to 266 at the end of the third quarter, from 285 in the second quarter.
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
The biotech has experienced a pullback in recent weeks.
Revolution Medicines has become one of the most eye-catching moves in biotech over the past few years, and the latest regulatory milestones now put a sharper spotlight on what investors are actually paying for on its balance sheet.
Revolution Medicines (RVMD) is back in focus after presenting new subgroup data from its Phase 3 RASolute 302 trial at the ESMO 2026 Congress in Madrid, highlighting overall survival outcomes with RASONQUE in metastatic pancreatic cancer.